Scilex Holding Co
NASDAQ:SCLX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Scilex Holding Co
Cash from Financing Activities
Scilex Holding Co
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Scilex Holding Co
NASDAQ:SCLX
|
Cash from Financing Activities
$23.6m
|
CAGR 3-Years
805%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$5.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
-$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
-11%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
-$10.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$1.9B
|
CAGR 3-Years
40%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
-$2.2B
|
CAGR 3-Years
26%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Scilex Holding Co
Glance View
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 2 full-time employees. The company went IPO on 2021-01-11. The firm's commercial product, ZTlido (lidocaine topical system) 1.8%, or ZTlido, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also commercializes Gloperba (colchicine USP) oral solution, a prophylactic treatment for painful gout flares in adults. The firm's three product candidates are SP-102 or SEMDEXA, a Phase 3, viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; SP-103 5.4%, a Phase 2, triple-strength formulation of ZTlido, for the treatment of low back pain; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia in multiple Phase 1 program.
See Also
What is Scilex Holding Co's Cash from Financing Activities?
Cash from Financing Activities
23.6m
USD
Based on the financial report for Dec 31, 2023, Scilex Holding Co's Cash from Financing Activities amounts to 23.6m USD.
What is Scilex Holding Co's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
805%
Over the last year, the Cash from Financing Activities growth was 11%. The average annual Cash from Financing Activities growth rates for Scilex Holding Co have been 805% over the past three years .
